Guggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).The analyst comments "Spyre announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'April 13, 2026 8:21 AM Spyre reports positive trial results for ulcerative colitis drug SPY001April 13, 2026 7:00 AM Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsApril 13, 2026 7:00 AM Spyre Therapeutics (SYRE) Halted, News PendingApril 13, 2026 6:56 AM Form ARS Spyre Therapeutics, Inc. For: Dec 31April 10, 2026 4:14 PM Form DEFA14A Spyre Therapeutics, Inc. April 10, 2026 4:05 PM Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026April 10, 2026 4:05 PM Form DEF 14A Spyre Therapeutics, Inc. For: May 27April 10, 2026 4:02 PM